What Research Shows About Automated Insulin Delivery Systems for Young People With Type 1 Diabetes
A comprehensive review of clinical trials found that automated insulin delivery systems consistently help children and adolescents spend more time in their target blood sugar range. Here's what the evidence shows about how these systems work and what families should know.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Automated insulin delivery (AID) systems, which combine continuous glucose monitoring with computer-guided insulin dosing, improved time in target blood sugar range across multiple studies in children and teens
- Young people using AID systems typically spent 7 to 12 percentage points more time in their target glucose range (70–180 mg/dL) compared to conventional insulin therapy
- Researchers reviewed 11 randomized controlled trials involving children as young as 2 years old, with studies lasting from 12 to 104 weeks
- The safety profile of these systems was considered in the analysis, though specific safety findings warrant discussion with your child's care team
How Researchers Evaluated AID Systems
Scientists conducted a systematic review of published research to understand how well automated insulin delivery systems work in children and adolescents with type 1 diabetes. They searched major medical databases through August 2026 and identified 11 high-quality randomized controlled trials—the gold standard for evaluating treatments.
The trials tested multiple different AID platforms in young people ranging from 2 to 18 years old. Some studies lasted 12 weeks, while others followed participants for up to 2 years. This range allowed researchers to evaluate both short-term performance and longer-term outcomes.
What the Evidence Shows About Time in Range
Across all the trials reviewed, AID systems consistently improved how much time young people spent with their blood sugar in the target range of 70–180 mg/dL. This measure, called 'time in range' or TIR, is an important indicator of diabetes management because it reflects how well glucose levels stay stable throughout the day.
Individual studies reported that children and adolescents using AID systems gained between 7 and 12 percentage points of additional time in range. For example, one trial showed an 11-percentage-point improvement in time in range, while another demonstrated an 8.7-percentage-point increase along with a 0.4-percentage-point reduction in hemoglobin A1c—a measure of average blood sugar control over three months.
Understanding AID System Technology
Automated insulin delivery systems work by linking two established diabetes technologies: a continuous glucose monitor (CGM) that tracks blood sugar in real time, and an insulin pump. The key innovation is an algorithm—a set of computer instructions—that decides how much insulin to deliver based on glucose readings and trends.
This automation aims to reduce the moment-to-moment decision-making that families with type 1 diabetes typically manage manually. By adjusting insulin delivery automatically, AID systems may help prevent both high and low blood sugar episodes more effectively than traditional pump therapy or insulin injections alone.
What This Means for Families
While these research findings are encouraging, it's important to understand what they do and don't tell us. The studies show that AID systems can improve glycemic control in children and adolescents in a research setting. However, real-world results depend on many factors, including how well the system is used, individual differences in how each young person's body responds to insulin, and their daily routines.
If you're considering an AID system for your child, talk with your diabetes care team about whether one might be appropriate based on your child's age, type of diabetes, and your family's circumstances. Your team can also discuss the specific safety considerations and how to effectively use the technology as part of your overall management plan.
Evidence label
Source: Cureus. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryDiagnosis & Early DetectionA Simple Blood Test May Help Doctors Assess How Severe Your DKA IsPubMed indexed literature
- Research summaryDiagnosis & Early DetectionA New Approach to Finding Type 1 Diabetes Early: Testing During Routine CheckupsPubMed indexed literature
- Research summaryDiagnosis & Early DetectionSingle Autoantibody: What It Means When Your Child Tests Positive for One Type 1 MarkerPubMed indexed literature
- Research summaryDiagnosis & Early DetectionKetosis-Prone Type 2 Diabetes: New Clues to an Immune Mix-UpPubMed indexed literature
- Research summaryDiagnosis & Early DetectionWhy Screening for Type 1 Diabetes Before Symptoms MatterPubMed indexed literature
- Research summaryDiagnosis & Early DetectionTesting for Type 1 Before Symptoms Appear: What a Real-World Pilot LearnedPubMed indexed literature